A new CT-scan based risk score facilitates the identification of patients at risk of revision endoscopic sinus surgery due to chronic rhinosinusitis.

A new CT-scan based risk score facilitates the identification of patients at risk of revision endoscopic sinus surgery due to ...

A device that releases a corticosteroid into the sinonasal cavity when patients exhale may improve sleep quality in chronic ...

The following is a summary of "Real-world comparison of T2-biologics effectiveness in severe allergic asthma with nasal ...

Using nasal swabs to identify a child’s asthma subtype may lead to more precise medication prescribing and development of ...

Among patients with previous sinus surgery for chronic rhinosinusitis with nasal polyps, the number of past surgeries did not ...

Afrin (oxymetazoline) and Flonase (fluticasone) are two common nasal sprays that work differently to help relieve nasal ...

Vasomotor rhinitis is a cause of runny nose and congestion not related to allergies or an infection. Learn about the symptoms ...

OptiNose stock surges 53% as it is set to be acquired by Paratek for $330 million, adding chronic rhinosinusitis drug, Xhance, to the latter's portfolio.

Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ~10‑million‑patient marketAcquisition advances Paratek’s ...